IP Library Granted Patent US 8,138,202
Granted Patent B2
US 8,138,202 · App. 12/982,785 · Granted Mar 20, 2012

Stable SNS-595 compositions and methods of preparation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,138,202
App. No.
12/982,785
Granted
Mar 20, 2012
Kind
B2
Abstract

Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.

Claims (9)

1. A composition comprising substantially pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid substance, wherein the substantially pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid substance comprises about 0 to 0.02% Compound 4

and about 0 to 0.02% Compound 5

based on total weight of the substantially pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid substance.

2. An aqueous solution comprising the composition of claim 1 and water, wherein about 100 mg of substantially pure (−)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid substance is present for every 10 mL of the aqueous solution, the aqueous solution is essentially free of visible particles, and the aqueous solution maintains not more than 1000 particles ≧10 microns per 10 mL of the aqueous solution when stored for at least 1 month.

3. The aqueous solution of claim 2 , wherein the aqueous solution consists essentially of 100 mg substantially pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid substance, 450 mg sorbitol, water, and methanesulfonic acid, wherein the pH of the aqueous solution is about 2.5, and wherein water is present in an amount to provide a total solution volume of 10 mL.

4. The aqueous solution of claim 2 , wherein the aqueous solution is stable with respect to visible particles when contacted with a compound capable of transforming Compound 4

to Compound 6

5. The aqueous solution of claim 2 , wherein the aqueous solution maintains not more than ≧10 microns per 10 mL of the aqueous solution when stored for at least 6 months.

6. An aqueous solution comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and water, wherein about 100 mg of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid is present for every 10 mL of the aqueous solution, and the aqueous solution maintains not more than 1000 particles ≧10 microns per 10 mL of the aqueous solution when stored for at least 1 month.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Nov 5, 2020
From: WESTERN ALLIANCE BANK
To: SUNESIS PHARMACEUTICALS, INC.
Reel/Frame 054335/0429 →
SECURITY INTEREST Recorded May 10, 2016
From: SUNESIS PHARMACEUTICALS, INC.
To: WESTERN ALLIANCE BANK
Reel/Frame 038655/0493 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2016
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: SUNESIS PHARMACEUTICALS, INC.
Reel/Frame 038330/0382 →
SECURITY AGREEMENT Recorded May 7, 2012
From: SUNESIS PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 028169/0528 →